[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kaohsiung Veterans General Hospital.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":235},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,73,105,134,156,183,211],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100634823","neuromuscular-control-and-motor-unit-behavior-in-patients-with-knee-osteoarthritis-100634823",false,"NCT07544693","Neuromuscular Control and Motor Unit Behavior in Patients With Knee Osteoarthritis","Neuromuscular Control and Motor Unit Behavior in Patients With Knee Osteoarthritis: a Randomized Single-blind Trial of Muscle Training and Knee Orthosis Intervention","Inclusion Criteria:\n\n\\- 1. age 55 to 75 years.\n\n2\\. Diagnosed with moderate knee traumatic arthritis (Kellgren-Lawrence classification II or III)(experimental group).\n\nThe control group must not have a diagnosis of osteoarthritis of the knee and must have normal knee joint function.\n\n3\\. Physical Health Status: Able to perform basic movements requiring isometric knee contraction tests and electromyography recording.\n\n4\\. Able to wear knee orthotics.\n\nExclusion Criteria:\n\n* 1\\. Knee or lower extremity injury: Recent (within the past 6 months) history of severe injury, fracture, or surgery to the knee or lower extremity.\n\n  2\\. Other joint disorders: Coexisting joint disorders (such as rheumatoid arthritis or gouty arthritis).\n\n  3\\. Neuromuscular disorders: Presence of neuromuscular dysfunction, such as stroke, Parkinson's disease, or peripheral neuropathy.\n\n  4\\. Uncontrolled cardiovascular disease, hypertension, diabetes, or other medical conditions.\n\nTaking medications that affect neuromuscular function.\n\n5\\. Allergy or intolerance: Allergy to laboratory equipment (such as electromyography electrode gel) or knee brace materials.",true,"ALL","55 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to examine the effects of moderate-intensity strength training, performed with or without an unloading knee orthosis (valgus-corrective or sham mode), on muscle function, motor unit behavior, and force modulation in patients with moderate knee osteoarthritis",[28],"Knee Osteoarthritis (Knee OA)",[30,31],"Orthotic Devices","knee osteoarthritis","NOT_YET_RECRUITING","2026-04-18",{"date":35,"type":36},"2026-04-22","ACTUAL",{"date":38,"type":22},"2026-04-20",{"date":40,"type":22},"2027-12-31",{"name":42,"class":43},"Kaohsiung Veterans General Hospital.","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100519654","early-diagnosis-of-breast-cancer-related-lymphedema-100519654","NCT06046365","Early Diagnosis of Breast Cancer-related Lymphedema","Inclusion Criteria:\n\n* Female patients who are expected to undergo breast cancer resection surgery or have already undergone breast resection surgery for breast cancer.\n* Absence of unhealed open wounds or other conditions unsuitable for tactile measurements within the measurement area.\n* No severe cognitive or emotional impairments.\n* No substance abuse (alcohol or drugs).\n* Females aged between 20 and 80, capable of fully complying with the requirements of this study plan.\n\nExclusion Criteria:\n\n* Presence of unhealed open wounds or other conditions unsuitable for tactile measurements within the measurement area.\n* Upper limb abnormalities in function (including joint mobility and muscle strength).\n* Significant cognitive, auditory, or expressive language issues that hinder comprehension and compliance with instructions.\n* Lack of assistance for daily measurements.","FEMALE","20 Years","80 Years",{"count":54,"type":22},300,"OBSERVATIONAL","This study will conduct clinical trials to explore the mechanisms behind the development of upper limb lymphedema following breast cancer surgery. The investigators will recruit patients who have undergone breast cancer surgery and utilize Indocyanine Green (ICG) lymphography and Lymphoscintigraphy to identify the locations of lymphatic blockages. Shear Wave Elastography (SWE) will be used to detect changes in tissue limb compliance. DXA body composition analysis will measure the differences in the composition ratios between edematous and normal limbs. In addition, diffusion correlation spectrometry will be employed to monitor changes in deep tissue blood flow, complemented by continuous measurements of limb circumference and other physiological parameters. The study aims to explore the interrelationships among lymphatic circulation, limb circumference, tissue compliance, and tissue blood flow rates.",[58],"Lymphedema",[60,61,62],"lymphoedema","limb circumference","tissue hardness","RECRUITING","2025-06-08",{"date":66,"type":36},"2025-06-11",{"date":68,"type":36},"2022-10-24",{"date":70,"type":22},"2026-12-31",{"name":42,"class":43},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":92,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":72},"100575859","phase-4-comparison-of-remimazolam-and-propofol-in-endoscopic-examinations-and-treatments-100575859","NCT06777758","Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments","The Comparison of Remimazolam or Propofol Used Alone Versus in Combination for Moderate Sedation During Endoscopic Examination and Treatment.","Remimazolam","Inclusion Criteria:\n\n* Subjects are between 20-80 years old.\n* Anesthesiologists rated ASA as between I and III.\n* Patients undergoing upper gastrointestinal endoscopic examination or therapy.\n\nExclusion Criteria:\n\n* Allergy to Propofol, Remimazolam, or opioid medications.\n* Emergency surgery.\n* Pregnancy.\n* History of malignant hyperthermia.\n* Impaired liver or kidney function.\n* Airway difficulties due to pharyngeal tumors.\n* Refusal to participate.",{"count":82,"type":22},90,[84],"PHASE4","This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.",[87,88,89,90,91],"Postoperative Complications","Respiratory Depression","Postoperative Nausea","Vomiting","Constipation",[93,94,95,96,97],"endoscope","Respiratory depression","Remimazolam、","Sedation","BYFAVO","2025-05-06",{"date":100,"type":36},"2025-05-08",{"date":102,"type":36},"2025-02-12",{"date":70,"type":22},{"name":42,"class":43},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":5},"100572023","phase-3-short-course-regimen-in-low-risk-active-tuberculosis--a-multicenter-randomized-active-controlled-trial-100572023","NCT06727864","Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial","Safety and Efficacy of Four-month Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Newly diagnosed pulmonary tuberculosis patients combined with any of the following diagnostic conditions:\n\n  * at least one set of sputum specimens is positive for Mycobacterium tuberculosis culture or TB PCR test; or\n  * pathological and histological findings of typical tuberculosis manifestations;\n  * clinical diagnosis and Physician determines the need for complete anti-tuberculosis treatment\n* Those who have had tuberculosis in the past and have been cured for at least three years can be included\n* Aged over 20 years old\n* Laboratory data at the time of inclusion in the study or within 14 days:\n\n  * Serum or plasma glutamic acid pyruvate transaminase (ALT) value ≦ three times the upper limit of normal\n  * Serum or plasma total bilirubin ≦ 2.5 times the upper limit of normal\n  * Serum or plasma creatinine ≦ twice the upper limit of normal or creatinine clearance greater than 30 mL\u002Fmin\n  * Heme ≧7.0 g\u002FDl\n  * Platelets ≧100,000\u002Fmm3\n* Patient signs consent form\n* Patients who agree to join and cooperate with the county and city health bureau's urban treatment plan to ensure medication compliance.\n\nExclusion Criteria:\n\n* The acid-fast smear of sputum or respiratory specimen is strongly positive (≥ 2+)\n* Chest X-ray or lung computed tomography combined with open lesions\n* Chest X-ray or lung computed tomography shows extensive lesions and the clinician judges that short-term treatment is not suitable\n* Simultaneous combination of intrapulmonary and extrapulmonary tuberculosis\n* People who are unable to take oral medications\n* People who have participated in this research\n* Have used anti-tuberculosis drugs for more than 14 days\n* A history of tuberculosis suspected or diagnosed as central nervous system tuberculosis, bone or joint tuberculosis, miliary tuberculosis or tuberculous pericarditis.\n* Known history of allergy or intolerance to this study drug\n* Patients with HIV infection, organ transplantation, and chronic renal failure\n* Long-term use of immunosuppressive drugs, including steroid use \\>10mg\u002Fday (more than 30 consecutive days in the last three months)\n* Late exclusion: Mycobacterium tuberculosis is known to be resistant to any one or more of the following drugs: rifampin, isoniazid, ethambutol","99 Years",{"count":114,"type":22},270,[116],"PHASE3","Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an endemic area for TB. The development of efficacious, safe, and shorter treatment regimens could significantly improve treatment completion rate and reduce transmission of TB. The current treatment guidelines for drug-susceptible TB from the World Health Organization (WHO), American Thoracic Society (ATS), United States Center for Diseases Control (U.S. CDC), Infectious Diseases Society of America (IDSA) and European Respiratory Society (ERS) include 2 months of isoniazid, rifampin, pyrazinamide and ethambutol (HREZ), followed by 4 months of isoniazid, rifampin, and ethambutol(HRE). The current treatment regimen requires 6 months of treatment, despite being highly efficacious, requires long duration of treatment. Adherence to treatment is the major barrier which poses a negative impact to TB control, and increased cost to both the patient and the public health system. Developing an efficacious, safe and short treatment regimen can significantly improve TB management and treatment success rates.",[119],"Pulmonary Tuberculosis",[121,122,123,124,125],"tuberculosis","short course regimen","safety","sputum conversion","recurrence rate","2025-03-21",{"date":128,"type":36},"2025-03-25",{"date":130,"type":36},"2024-01-01",{"date":132,"type":22},"2028-12-31",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":50,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":72},"100577815","effects-of-lh-and-fsh-on-metabolic-regulation-in-cumulus-cells-100577815","NCT06803199","Effects of LH and FSH on Metabolic Regulation in Cumulus Cells","Investigation of the Combined Effects of Luteinizing Hormone and Follicle-Stimulating Hormone on Metabolic Regulation in Cumulus Cells","Inclusion Criteria:\n\n* Age 35-40 years\n* BMI 18-30 kg\u002Fm2\n* planning to undergo IVF cycles\n\nExclusion Criteria:\n\n* Primary ovarian insufficiency\n* history of oophorectomy\n* receiving oocyte donation\n* Chromosome anomaly\n* Congenital uterine anomaly\n* Severe intrauterine adhesion\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","35 Years","40 Years",{"count":144,"type":22},60,[25],"The combined use of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) has improved IVF pregnancy rates in infertile women aged 35-40, but its mechanisms remain unclear. This prospective study will examine how FSH and LH combined treatment affects cumulus cell energy metabolism. Sixty participants will be divided into two groups receiving either combined therapy or FSH alone. The study will analyze patient characteristics, infertility history, and compare mitochondrial function in cumulus cells to evaluate treatment effectiveness.",[148],"Unrecognized Condition","2025-01-27",{"date":151,"type":36},"2025-01-31",{"date":153,"type":36},"2024-12-01",{"date":40,"type":22},{"name":42,"class":43},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":50,"minAge":141,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":72},"100558104","the-effect-of-melatonin-supplementation-on-cumulus-cells-and-ivf-outcomes-100558104","NCT06546774","The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes","The Effect of Melatonin Supplementation on Cumulus Cells and Reproductive Outcomes in Older Women Undergoing IVF Cycles","Inclusion Criteria:\n\n* Age 35-45 years\n* BMI 18-30 kg\u002Fm2\n* planning to undergo IVF cycles\n\nExclusion Criteria:\n\n* Primary ovarian insufficiency\n* history of oophorectomy\n* receiving oocyte donation\n* Chromosome anomaly\n* Congenital uterine anomaly\n* Severe intrauterine adhesion\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","45 Years",{"count":165,"type":22},200,[25],"This study investigates the effects of melatonin supplementation on cumulus cell gene expression and in vitro fertilization (IVF) outcomes in women over 35 years old. In the study group, patients will receive melatonin supplementation for at least two months prior to their IVF cycles. Cumulus cells will be collected after oocyte retrieval, and IVF outcomes will be assessed.",[148],[170,171,172,173,174],"Melatonin","Cumulus cells","In vitro fertilization","Old women","Infertility","2024-08-09",{"date":177,"type":36},"2024-08-13",{"date":179,"type":36},"2021-05-01",{"date":181,"type":22},"2025-12-31",{"name":42,"class":43},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":16,"sex":190,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":72},"100542217","male-supplements-for-sperm-quality-and-aging-100542217","NCT06339996","Male Supplements for Sperm Quality and Aging","To Investigate Supplements for Improving Male Sperm Quality and Combating Aging","Inclusion Criteria:\n\n* Not meet the criteria of the 6th edition of the WHO manual for human semen analysis\n* BMI:18-30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Azoospermia\n* Varicocele\n* Chromosome anomaly\n* Malignancy\n* Using hormone therapy or supplements in recent 3 months","MALE","30 Years","50 Years",{"count":194,"type":22},50,[25],"This study investigates the effects of a new supplement on sperm quality in men with poor sperm quality. Fifty patients will receive the supplement for three months, followed by semen analysis and assessment of sperm aging and mitochondrial function. Changes in sexual function and aging symptoms will also be evaluated.",[148],[199,200,201,202,203],"Male supplement","Sperm quality","Aging","Mitochondrial function","Sexual function","2024-08-01",{"date":206,"type":36},"2024-08-02",{"date":208,"type":36},"2024-03-26",{"date":181,"type":22},{"name":42,"class":43},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":72},"100447171","the-effect-of-self-rehabilitation-using-communication-app-after-arthroscopic-surgery-for-rotator-cuff-tear-100447171","NCT05102968","The Effect of Self-rehabilitation Using Communication APP After Arthroscopic Surgery for Rotator Cuff Tear","Using a Mobile APP to Support Home-based Rehabilitation for Patients With Rotator Cuff Tear After Arthroscopic Repair","Inclusion Criteria:\n\n* patients had a small to medium-sized (less than 3 cm) full-thickness rotator cuff tear or, a Lafosse type II or III subscapularis tear diagnosed and repaired by shoulder arthroscope\n* patients were willing to consent to post-operative rehabilitation randomization and commit to the two-year clinical follow-up period.\n\nExclusion Criteria:\n\n* pre-operative shoulder stiffness (defined as passive forward elevation less than 100 degrees and external rotation loss over 50% comparing to the contralateral side)\n* an intra-operative irreparable cuff tear\n* a prior ipsilateral shoulder surgery\n* a history of systemic auto-immune disease or septic arthritis of the ipsilateral shoulder","70 Years",{"count":144,"type":22},[25],"The purpose of this study was to assess the clinical effect of a mobile application supporting home-based rehabilitation for the patients after arthroscopic rotator cuff repair. The investigators hypothesized the clinical results of the patients using a mobile application (APP) to support the home-based rehabilitation were comparable to the patients receiving the supervised rehabilitation.\n\nThis prospective randomized case-control study was approved by the institutional review board of the Kaohsiung Veteran General Hospital (IRB No. KSVGH18-CT12-15) prior to enroll any patients. Patients were recruited if they had a small to medium-sized full-thickness rotator cuff tear or, a Lafosse type II or III subscapularis tear diagnosed and then repaired under shoulder arthroscope. After the surgery, patients were randomized either to the home-based rehabilitation (the home group) or the hospital supervised rehabilitation (the supervised group).\n\nIn the home group, patients self-managed rehabilitation exercise without supervision. Rehabilitation were supportive with the APP. Patient could communicate with the physician via the APP. In the supervised group, patients attended one-on-one instructions with therapists and exercised under supervision at hospital.\n\nPatients' characters were recorded. Peri-operative factors associated with rotator cuff healing were assessed. The active ROM (forward elevation, abduction, external and internal rotation), the visual analogue scale (VAS) pain scores, the American shoulder and elbow surgeon shoulder (ASES) scores and the modified Constant scores were recorded pre-operatively and post-operatively 3, 6, 12 and 24 months. The isometric shoulder strength was assessed with the hand-held dynamometer. The compliance of post-operative rehabilitation was evaluated not only from patients' self-reported logs but also by physicians at post-operatively 6, 12 and 24 weeks. Tendon integrity was evaluated with MRI scan at least 6 months after the index surgery. In the pilot study, we found a mean difference of 4 points and a standard deviation of 5.5 points in the modified Constant scores. Power analysis revealed a total sample size of 62 patients (31 patients in each group) would achieve a statistical power of 0.8 with a two-tailed level of 0.05 to detect significant differences. Statistical level of significance was defined as p\\\u003C0.05.",[223],"Rotator Cuff Tears",[225,226,227],"Rotator cuff tear","Arthroscopic surgery","Telerehabilitation","2021-11-01",{"date":230,"type":36},"2021-11-02",{"date":232,"type":36},"2019-03-22",{"date":70,"type":22},{"name":42,"class":43},""]